Takeda books JPY 402.5 billion legal provision after AMITIZA antitrust verdict

  • Takeda revised FY2025 reported results to reflect a U.S. jury verdict in AMITIZA antitrust litigation.
  • Booked an additional legal provision of JPY 402.5 billion; recognized related tax benefits of JPY 58.4 billion.
  • Core FY2025 results unchanged; FY2026 forecast, management guidance, adjusted free cash flow outlook unchanged.
  • Plans post-trial motions and an appeal; seeks a stay of judgment execution during the appeal.
  • Liability not yet finalized; expects no material impact on FY2026 guidance from the litigation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief on June 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.